Replacement Student Loan * Related Tip Designed For Student Loan Weak Credit

College loans when Given., parent or guardian, or perhaps professional , their very own have lot of benefits and drawbacks. For this reason you must pick pacificdebt consolidationcarefully to protect yourself from obtaining horrible liabilities. To help you making that final choice, here are some fundamental information regarding you might use. In case you’re seeking [...]

Source: http://www.legaldebthelponline.com/2012/06/02/replacement-student-loan-related-tip-designed-for-student-loan-weak-credit/

debt negotiation companies debt payment calculator debt planner debt ratio calculator

Inside The Office Of SEO Company Conductor, One Of The Best Work Places In New York

amy phan, office tour, conductor, may 2012, bi, dng

Conductor is an SEO technology developer that creates software and platforms to help companies manage and improve their search engine optimization.

The company has placed a priority on creating a great work environment and they recently were named as the 4th Best Place to Work (Small/Medium sized company category) in New York State by Crain's 2012 survey.

With a light subway theme and an emphasis on teamwork, employee recognition and rewards, and an open, relaxed work environment the office had plenty of fun surprises throughout.

We got the Conductor office, which is just down the block from Business Insider, and literally next door to Birchbox, another company we've toured.

Obligatory logo shot.

One of the first people you see on entry is Michael "The Hoff" Hoffman busy on the phone making sales happen.

See the rest of the story at Business Insider

Please follow SAI on Twitter and Facebook.

Source: http://feedproxy.google.com/~r/businessinsider/~3/-UT1DY42_jE/conductor-seo-company-workplace-pictures-2012-5

bad debt collection bad debt mortgage bad debt write off bankruptcy debt relief

New Breast Cancer Drug Is So Successful That Scientists Can't Even Determine The Survival Rate

CHICAGO (AP) — Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone.

In a key test involving nearly 1,000 women with very advanced disease, the experimental treatment extended by several months the time women lived without their cancer getting worse, doctors planned to report Sunday at a cancer conference in Chicago.

More importantly, the treatment seems likely to improve survival; it will take more time to know for sure. After two years, 65 percent of women who received it were still alive versus 47 percent of those in a comparison group given two standard cancer drugs.

That margin fell just short of the very strict criteria researchers set for stopping the study and declaring the new treatment a winner, and they hope the benefit becomes more clear with time. In fact, so many women on the new treatment are still alive that researchers cannot yet determine average survival for the group.

"The absolute difference is greater than one year in how long these people live," said the study's leader, Dr. Kimberly Blackwell of Duke University. "This is a major step forward."

A warning to hopeful patients: the drug is still experimental, so not available yet. Its backers hope it can reach the market within a year.

The treatment builds on Herceptin, the first gene-targeted therapy for breast cancer. It is used for about 20 percent of patients whose tumors overproduce a certain protein.

Researchers combined Herceptin with a chemotherapy so toxic that it can't be given by itself, plus a chemical to keep the two linked until they reach a cancer cell where the poison can be released to kill it.

This double weapon, called T-DM1, is the "smart bomb," although it's actually not all that smart — Herceptin isn't a homing device, just a substance that binds to breast cancer cells once it encounters them.

Doctors tested T-DM1 in 991 women with widely spread breast cancer that was getting worse despite treatment with chemotherapy and ordinary Herceptin. They were given either T-DM1 infusions every three weeks or infusions of Xeloda plus daily Tykerb pills — the only other treatments approved for such cases.

The median time until cancer got worse was nearly 10 months in the women given T-DM1 versus just over 6 months for the others. That is about the same magnitude of benefit initially seen with Herceptin, which later proved to improve overall survival, too, Blackwell said.

T-DM1 caused fewer side effects than the other drugs did. Some women on T-DM1 had signs of liver damage and low levels of factors that help blood clot, but most did not have the usual problems of chemotherapy.

"People don't lose their hair, they don't throw up. They don't need nausea medicines, they don't need transfusions," said Blackwell, who has consulted in the past for Genentech, the study's sponsor.

"The data are pretty compelling," said Dr. Michael Link, a pediatric cancer specialist at Stanford University who is president of the American Society of Clinical Oncology, the group hosting the Chicago conference where the results were being presented.

"It's sort of a smart bomb kind of therapy, a poison delivered to the tumor ... and not a lot of other collateral damage to other organs," he said.

Dr. Louis Weiner, director of Georgetown Lombardi Comprehensive Cancer Center, said the results strongly suggest T-DM1 improves survival. It delivers more drug directly to tumors with less side effects, "a clear advance," he said.

Denise Davis, 51, a customer service representative at a propane company, was diagnosed three years ago with breast cancer that had spread to her liver and bones. Since February of last year, the Lynchburg, Va., woman has made the two-hour trip to Duke in Durham, N.C., every three weeks to get infusions of T-DM1.

"I call it 'Herceptin-plus,'" she said. Scans every six weeks show "everything is still shrinking or stable," she said. "Right now, I'm feeling pretty good about it. The only way I'd feel a little better is if it took care of everything, but I'll take what I can get."

Genentech, part of the Swiss company Roche, plans to seek approval later this year to sell the drug in Europe and the United States. Another company, ImmunoGen Inc., made the technology combining the drugs.

Genentech says the price of T-DM1 has not been determined. Herceptin costs more than $4,000 a month plus whatever doctors charge to infuse it. Herceptin's U.S. patent doesn't expire until 2019.

___

Online:

Cancer conference: http://www.cancer.net

American Cancer Society: http://www.cancer.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Please follow Business Insider on Twitter and Facebook.

Join the conversation about this story »

Source: http://feedproxy.google.com/~r/businessinsider/~3/eC3mudsmzjU/new-breast-cancer-drug-is-so-successful-that-scientists-cant-even-determine-the-survival-rate-2012-6

debt advice uk debt advisor debt arbitration debt clearance

The Time Has Come, Don?t Blow It, Mr. Bernanke!

For the Fed, as the U.S. economic recovery stumbles again this summer, it's a much uglier backdrop than in the slowdowns of the last two summers. It makes it much less likely the Fed will luck out if it waits until the last minute to come to the rescue this time. In fact there's no assurance that the Fed even has firepower that will work this time

Source: http://www.forbes.com/sites/greatspeculations/2012/06/01/the-time-has-come-dont-blow-it-mr-bernanke/

debt repayment calculator debt rescue debt resolve debt settlement advice

Consolidation Loans can Save Your Credit

Trying to keep up with a number of credit card payments every month is not an easy thing to do. The average credit score in the country has dropped considerably in the past 5 years. Consolidation loans are a good way to keep your credit score where it should be. Make only one payment a [...]

Source: http://www.legaldebthelponline.com/2012/06/01/consolidation-loans-can-save-your-credit/

debt management group debt management software debt management uk debt managers ltd

BP May Sell Stake In Russian Subsidiary After Latest Round Of Trouble

BP?s announcement that it was considering an unsolicited proposal for its holding in TNK-BP is at odds with its earlier position of not being willing to part with its stake in the company despite recurring corporate governance issues.

Source: http://www.forbes.com/sites/greatspeculations/2012/06/01/bp-may-sell-stake-in-russian-subsidiary-after-latest-round-of-trouble/

debt settlement usa debt shield debt stoppers debt to income ratio calculator